Showing 1911-1920 of 2192 results for "".
- Endovascular Thrombectomy Improves Functional Outcomes Long Term in Patients with Large Vessel Occlusion Ischemic Strokehttps://practicalneurology.com/news/endovascular-thrombectomy-improves-functional-outcomes-long-term-in-patients-with-large-vessel-occlusion-ischemic-stroke/2470401/Endovascular thrombectomy (EVT) improved functional outcomes in patients with anterior circulation large vessel occlusion ischemic stroke and large ischemic core at 1 year of follow up, according to long-term results from the SELECT2 clinical trial (NCT03876457). EVT also met secondary outcomes a
- Anticoagulation Therapy Does Not Reduce Risk of Recurrent Stroke Compared with Aspirin in Those with Cryptogenic Stroke and Atrial Cardiopathyhttps://practicalneurology.com/news/anticoagulation-therapy-does-not-reduce-risk-of-recurrent-stroke-compared-with-aspirin-in-those-with-cryptogenic-stroke-and-atrial-cardiopathy/2470399/Treatment with Eliquis (apixaban; Bristol Myers Squibb, New York, NY), an anticoagulant medication, did not significantly reduce the risk of recurrent stroke compared with aspirin therapy in people with cryptogenic stroke and evidence of atrial cardiopathy. The findings of the ARCADIA clinical tr
- Boston Scientific’s Spinal Cord Stimulation Systems Effective at Reducing Back Painhttps://practicalneurology.com/news/boston-scientifics-spinal-cord-stimulation-systems-effective-at-reducing-back-pain/2470387/Using the WaveWriter and WaveWriter Alpha Spinal Cord Stimulation (SCS) Systems (Boston Scientific, Marlborough, MA) resulted in sustained pain relief as treatment for non-surgical back pain (NSBP), according to positive 1-year results from the SOLIS clinical trial (NCT04676022). These findi
- Promising Results from Study of Stem Cell Transplantation in People with Multiple Sclerosis Publishedhttps://practicalneurology.com/news/promising-results-from-study-of-stem-cell-transplantation-in-people-with-multiple-sclerosis-published/2470351/One-year results from a phase I clinical trial (NCT03282760) demonstrated the feasibility, safety, and tolerability of intracerebroventricular (ICV) human neural stem/progenitor cell (hNSC) transplantation in patients with secondary progressive multiple sclerosis (SPMS). Results were published in
- Breakthrough Device Designation Granted to Roche’s Elecsys Neurofilament Light Chain Test for Multiple Sclerosishttps://practicalneurology.com/news/breakthrough-device-designation-granted-to-roches-elecsys-neurofilament-light-chain-test-for-multiple-sclerosis/2470350/Roche’s Elecsys neurofilament light chain (NfL) test (Basel, Switzerland) received breakthrough device designation from the Food and Drug Administration (FDA). The test is intended to be used to detect disease activity in the serum and plasma of adults aged 18 to 55 years with relapsing-rem
- Recipients of the “Frontiers in Headache Research Scholarship Award” from the American Headache Society Announcedhttps://practicalneurology.com/news/recipients-of-the-frontiers-in-headache-research-scholarship-award-from-the-american-headache-society-announced/2470341/Ten recipients of the American Headache Society (AHS) Frontiers in Headache Research Scholarship Award have received complimentary meeting registration for the 2023 Scottsdale Headache Symposium, a travel stipend of up to $1000, and a full year of AHS Trainee membership. The AHS awards this schol
- Novel Therapies for Migraine Treatment Based on Updates in Migraine Pathophysiology Explored by Dr. Andrew Charles, UCLAhttps://practicalneurology.com/news/novel-therapies-for-migraine-treatment-based-on-updates-in-migraine-pathophysiology-explored-by-dr-andrew-charles-ucla/2470339/The 2023 Scottsdale Headache Symposium featured a presentation by Dr. Andrew Charles, “The Future of Headache Therapeutics,” in which he examined how advances in the understanding of migraine pathophysiology are leading to novel therapeutic possibilities for migraine treatment. His pr
- FDA Grants Fast Track Designation to Investigational RNA Replacement Enzyme-Based Cancer Gene Therapy to Treat Glioblastomahttps://practicalneurology.com/news/fda-grants-fast-track-designation-to-investigational-rna-replacement-enzyme-based-cancer-gene-therapy-to-treat-glioblastoma/2470336/RZ-001 (Rznomics; Yongin-si, South Korea), a candidate RNA replacement enzyme-based cancer gene therapy, has been granted Fast Track Designation by the Food and Drug Administration (FDA) for investigation as a potential treatment for patients with glioblastoma (GBM). RZ-001 is designed to target
- Long-Term Data from Real-World CLARENCE Study Show Stable Disability Outcomes in Patients with Highly Active Relapsing MS Treated with Mavencladhttps://practicalneurology.com/news/long-term-data-from-real-world-clarence-study-show-stable-disability-outcomes-in-patients-with-highly-active-relapsing-ms-treated-with-mavenclad/2470330/After 5 years of follow-up, people with highly active relapsing multiple sclerosis (RMS) treated with Mavenclad (cladribine tablets; Merck, Darmstadt, Germany) showed high rates of treatment persistence and low rates of switching to other disease-modifying therapies (DMTs). These results from an
- Agamree Receives FDA Approval as First “Dissociative Steroidal Anti-Inflammatory” to Treat Duchenne Muscular Dystrophyhttps://practicalneurology.com/news/agamree-receives-fda-approval-as-first-dissociative-steroidal-anti-inflammatory-to-treat-duchenne-muscular-dystrophy/2470327/Agamree (vamorolone; Catalyst Pharmaceuticals, Coral Gables, FL) has received Food and Drug Administration (FDA) approval as an oral suspension 40 mg/mL to treat Duchenne Muscular Dystrophy (DMD) in patients aged 2 years and older. Agamree was developed by Santhera Pharmaceuticals (Pratteln, Swit